Sydney, Feb 10, 2011 (ABN Newswire) - Calzada Limited (ASX:CZD) said today that its wholly owned subsidiary Metabolic Pharmaceuticals Pty Ltd had initiated an in vitro study into the effect of AOD9604 on human osteoblasts. AOD9604 performed positively in the study, demonstrating its ability to promote bone growth and to treat diseases such as osteoporosis. Calzada is seeking partnership with pharmaceutical and medical device companies to further develop AOD9604, either as a regulated drug through the traditional pharmaceutical development path or as a cosmetic or nutraceutical with a faster path to market.
